%D9%84%D9%8A%D9%86%D8%A7%D9%84%D9%8A%D8%AF%D9%88%D9%85%D9%8A%D8%AFCategory:LenalidomideLenalidomidLenalidomideLenalidomidaLenalidomidiL%C3%A9nalidomideLenalidomide%E3%83%AC%E3%83%8A%E3%83%AA%E3%83%89%E3%83%9F%E3%83%89LenalidomidasLenalidomida%D0%9B%D0%B5%D0%BD%D0%B0%D0%BB%D0%B8%D0%B4%D0%BE%D0%BC%D0%B8%D0%B4LenalidomidLenalidomidLenalidomideQ425681
about
P1056
Chronic myelomonocytic leukemiachronic lymphocytic leukemianon-Hodgkin lymphomacentral nervous system lymphomamyelofibrosisWaldenström's macroglobulinemiamature T-cell and NK-cell lymphomalymphoblastic leukemiamycosis fungoideslymphomaplasmacytomachromosome 5q deletion syndromediffuse large B-cell lymphomamantle cell lymphomaleukemiamultiple myelomaB-cell lymphomaanemiarefractory anemia with excess blasts in transformationPlasma cell leukemiaRefractory cytopenia with multilineage dysplasiaT-cell lymphomaamyloidosismyelodysplastic syndrome
P2176
P3355
P3781
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell LymphomaLenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin LymphomaClinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell LymphomaSVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance TherapyPhase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib MaintenanceEfficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in RemissionTrial on the Effect of Isatuximab to Lenaliodomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma PatientsPhase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MMVorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)Rituximab, Lenalidomide, and Bortezomib in Mantle Cell LymphomaValproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid TumorLenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple MyelomaA Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple MyelomaA Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic LeukemiaA Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving RevlimidA Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's DiseaseLenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple MyelomaLenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple MyelomaMulti-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003Lenalidomide Maintenance Post-debulking in Advanced CTCLLenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma PatientsLenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate CancerCyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma SubjectsLenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaEverolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaMaintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic LeukemiaLenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide MaintenanceA Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's LymphomaVorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing RegimensVorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance TherapySequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic TransplantationPilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple MyelomaLenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.Lenalidomide and GA101 in Relapsed Indolent Non-Hodgkin's LymphomaA Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
P4844
Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemiaThe clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro... A possible explanation for their mechanism of action in treating multiple myelomaGenomic stratification of multiple myeloma treated with novel agents.Advantageous use of lenalidomide in multiple myeloma: discussion of three case studies.Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma.Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma.A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomideSalvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomideThe extended 4-year follow-up results of the ELOQUENT-2 trialLenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in RemissionA Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple MyelomaA Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic LeukemiaLenalidomide and GA101 in Relapsed Indolent Non-Hodgkin's LymphomaNon-Interventional Study in Patients With Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) to Investigate the Association of Lenalidomide With Tumor Flare Reaction and High Tumor BurdenStudy to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1A Phase II Study of CC-5013 in MyelofibrosisIbrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL)A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" TrialLenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) PatientsLenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC SubtypeCombination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)Selective purging of human multiple myeloma cells from peripheral blood mononuclear cells: a preliminary studyMultiple myeloma with dural mater involvementEffectiveness of lenalidomide in relapsed primary cutaneous diffuse large B-cell lymphoma, leg typeEffective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapyp53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomideA Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple MyelomaEarly Detection of Neuropathy and Cognitive Impairment Following Treatment for Haematological Malignancies
P921
Q1088072-E1FA92F6-B6A1-4F03-B514-85891AB9B5B5Q1088156-F6868FAA-AFA6-4662-8DF4-AD17CD73F9ADQ1138590-64015D7B-3424-4C0A-94F4-36A55DC293A9Q136312-55AD3A30-95C1-42A7-8323-2AEB29F3C932Q1752571-ADE9506C-59A7-4A11-A4A7-745037E93478Q1778287-33B13276-2231-4193-B9E3-93B2B43E83D6Q18553445-7934CE60-C8F8-4A50-921C-EDD47090FA42Q18553852-360408E2-FC18-4478-AB95-E8CBE36BB855Q1891209-DB6E7662-FA53-4763-84BD-CF9A46C67167Q208414-9352A15B-3C9F-423D-81AF-4A03B9EE3220Q2090167-EE08B597-5BA4-4CA9-90B4-2595FDB7E619Q245455-B20A9351-795F-4C81-9E56-0D5D3D258D89Q2626074-A82CA717-8FE2-4D5D-A2F6-FF7451CB825FQ268713-333AE1B3-AF2C-405A-B26D-EC375E849DD6Q29496-09C4D34B-29E1-49F9-92E8-6F65659F77B8Q467635-BA8F5068-714B-4B4C-BDC3-25AED5D14D63Q4833719-6012F942-CAA2-4678-8C71-8CEA8027C295Q5445-0844AA4A-8404-471F-B58A-84EFDFBC5C78Q55785650-B3CA7382-7967-41EB-96A3-4E60964CA65AQ7201765-3B7B5A4A-609C-4AB1-91C1-4E46CB85DFC5Q7307574-ABD2715E-5186-46EB-A1B8-B0AACD56EF4CQ7667896-ADB5EE08-6F4B-4461-A490-FBD2711B7243Q816798-F4425978-F2C6-4F10-9180-82F8BB6DB30FQ954625-0708D332-7AE6-45E3-8682-28C719184E51
P2176
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische stof
@nl
name
Lenalidomid
@de
Lenalidomid
@sh
Lenalidomid
@sr
Lenalidomidas
@lt
Lenalidomide
@nl
Lenalidomide
@vi
Lenalidomidi
@fi
lenalidomid
@nn
lenalidomida
@ca
lenalidomida
@es
type
label
Lenalidomid
@de
Lenalidomid
@sh
Lenalidomid
@sr
Lenalidomidas
@lt
Lenalidomide
@nl
Lenalidomide
@vi
Lenalidomidi
@fi
lenalidomid
@nn
lenalidomida
@ca
lenalidomida
@es
altLabel
1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
@en
1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
@en
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
@en
C13H13N3O3
@fr
CC-5013
@en
CDC 501
@en
CDC-501
@en
IMiD3
@en
IMid-1
@en
Le lénalidomide
@fr
prefLabel
Lenalidomid
@de
Lenalidomid
@sh
Lenalidomid
@sr
Lenalidomidas
@lt
Lenalidomide
@nl
Lenalidomide
@vi
Lenalidomidi
@fi
lenalidomid
@nn
lenalidomida
@ca
lenalidomida
@es